193. Prader-Willi syndrome Clinical trials / Disease details


Clinical trials : 111 Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02810483
(ClinicalTrials.gov)
December 201217/5/2016Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 WeeksRandomized, Placebo Controlled Double-blind Study of the Efficacy of Topiramate on the Symptoms of Irritability - Impulsivity, Overeating and Self-harm in a Population of Patients Suffering From Prader Willi Syndrome Over 8 WeeksPrader-Willi SyndromeDrug: Topiramate;Drug: Placebo ComparatorAssistance Publique - Hôpitaux de ParisNULLTerminated12 Years45 YearsAll69Phase 3France
2NCT00065923
(ClinicalTrials.gov)
July 20021/8/2003Treatment of Self-Injurious Behavior in Individuals With Prader-Willi SyndromeTopiramate Effects on SIB in Prader-Willi SyndromePrader-Willi Syndrome;Self-Injurious BehaviorDrug: TopiramateEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLCompleted18 Years66 YearsBoth10N/AUnited States
3EUCTR2011-003432-32-FR
(EUCTR)
13/10/2011N/AN/A - TOPRADER
MedDRA version: 14.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Trade Name: Topiramate
Product Name: Topiramate
INN or Proposed INN: topiramate
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot Recruiting Female: yes
Male: yes
125 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance